Myelodysplastic Syndromes Clinical Trials

73 studies are recruiting for myelodysplastic syndromes in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)

   Patients with clonal cytopenia of undetermined significance (CCUS) and lower-risk myelodysplastic syndromes (MDS) have a life expectancy of 5 to 10 years. Mortality in these patients results from progression of disease to higher-risk MDS or acute myeloid leukemia (AML) and cardiovascular events. Cu…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Run by

   Washington University School of Medicine

   See if you can join NCT05483010 on ClinicalTrials.gov

2. Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens

   This research study is a genomic profiling and repository study for children and young adults who have leukemia, myelodysplastic syndrome (MDS) or myeloproliferative syndrome (MPS). Genes are the part of cells that contain the instructions which tell cells how to make the right proteins to grow and…

   Stage

   Not phased

   Ages

   Up to 30

   Site

   Connecticut Children's Medical Center, Hartford, Connecticut

   Locations

   8 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04968834 on ClinicalTrials.gov

3. HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

   This is a Phase I dose finding study of GTB-3650 (anti-CD16/IL-15/anti-CD33) Tri-Specific Killer Engager (TriKE®) for the treatment of select CD33-expressing refractory/relapsed myeloid malignancies in adults ≥ 18 years of age who are not a candidate for potentially curative therapy, including hema…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Masonic Cancer Center, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT06594445 on ClinicalTrials.gov

4. CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT

   The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconst…

   Stage

   Not phased

   Ages

   Up to 25

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Run by

   Children's Hospital of Philadelphia

   See if you can join NCT03810196 on ClinicalTrials.gov

5. Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

   This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunotherapy biologic manuf…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UCLA Department of Medicine, Los Angeles, California

   Locations

   6 in total

   Run by

   Orca Biosystems, Inc.

   See if you can join NCT07216443 on ClinicalTrials.gov

6. Allo HSCT Using RIC and PTCy for Hematological Diseases

   This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamid…

   Stage

   Phase 2

   Ages

   Up to 75

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT05805605 on ClinicalTrials.gov

7. Registry of Older Patients With Cancer

   RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.

   Stage

   Not phased

   Ages

   65 and older

   Site

   Seby B. Jones Cancer Center, Boone, North Carolina

   Locations

   7 in total

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT01137825 on ClinicalTrials.gov

8. Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

   The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   University of Illinois Cancer Center, Chicago, Illinois

   Run by

   University of Illinois at Chicago

   See if you can join NCT06802315 on ClinicalTrials.gov

9. Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

   The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   Stanford University, Palo Alto, California

   Run by

   Stanford University

   See if you can join NCT06551584 on ClinicalTrials.gov

10. A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

    This research study is studying cytokine induced memory-like natural killer (CIML NK) cells combined with IL-2 in adult patients (18 years of age or older) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) who relapse after haploidentical hemat…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Boston Children's Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04024761 on ClinicalTrials.gov

11. Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

    The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MP…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT06138587 on ClinicalTrials.gov

12. Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

    The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will re…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Medical University of South Carolina, Charleston, South Carolina

    Locations

    30 in total

    Run by

    Institut de Recherches Internationales Servier

    See if you can join NCT02074839 on ClinicalTrials.gov

13. Investigation of the Genetics of Hematologic Diseases

    The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings…

    Stage

    Not phased

    Ages

    Any age

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT02720679 on ClinicalTrials.gov

14. A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

    To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05365035 on ClinicalTrials.gov

15. Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

    This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic synd…

    Stage

    Phase 2

    Ages

    0 to 39

    Site

    University of Florida, Gainesville, Florida

    Run by

    University of Florida

    See if you can join NCT05800210 on ClinicalTrials.gov

16. Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

    The purpose of this study is to determine if hyperbaric oxygen therapy is safe in the setting of stem cell transplantation. This study will also determine if hyperbaric oxygen therapy improves engraftment, graft versus host disease, neutrophil count, and incidence and severity of mucositis (inflamm…

    Stage

    EARLY_Phase 1

    Ages

    18 to 75

    Site

    Wilmot Cancer Institute, University of Rochester, Rochester, New York

    Run by

    Omar Aljitawi

    See if you can join NCT03964506 on ClinicalTrials.gov

17. A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

    The goal of this clinical trial is to determine if momelotinib is safe and effective for people with low-risk myelodysplastic syndromes (LR-MDS). The trial will also examine how the body processes the drug. Participants will receive different doses of momelotinib to find the best dose by evaluating…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    GSK Investigational Site, Goodyear, Arizona

    Locations

    39 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT06847867 on ClinicalTrials.gov

18. Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

    This is a Phase 1b, multicenter, open-label, PK, and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with severe renal impairment and cance…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson, Houston, Texas

    Locations

    21 in total

    Run by

    Taiho Oncology, Inc.

    See if you can join NCT04953897 on ClinicalTrials.gov

19. Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

    This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with moderate and se…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson, Houston, Texas

    Locations

    22 in total

    Run by

    Taiho Oncology, Inc.

    See if you can join NCT04953910 on ClinicalTrials.gov

20. 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies

    Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where components of blood such as red cells, platelets and white cells are made. In bone marrow failure, the ability for bone marrow to make these cells is decreased. In myelodysplastic syndrome, this decreased bon…

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio

    Run by

    Benjamin Tomlinson

    See if you can join NCT04187703 on ClinicalTrials.gov

21. Cord Blood Transplantation in Children and Young Adults With Blood Cancer

    The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.

    Stage

    Phase 2

    Ages

    Up to 26

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07566377 on ClinicalTrials.gov

22. Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

    The purpose of this study is to understand the safety and estimate the efficacy of combining anti-CD3 x anti-CD33 bispecific antibody (CD33Bi) armed fresh peripheral blood mononuclear cells (CD33Bi FPBMC) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) where they st…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Virginia, Charlottesville, Virginia

    Run by

    University of Virginia

    See if you can join NCT07270978 on ClinicalTrials.gov

23. Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

    Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood. Several alterations that occur repeatedly in certain types of blood cancers have already been identified, and these …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    7 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT02269592 on ClinicalTrials.gov

24. Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes

    The goal of this interventional clinical trial is to evaluate the safety and tolerability of leflunomide in combination with decitabine as treatment for patients with relapsed or refractory myelodysplastic syndromes (R/R MDS). The main question this study aims to answer are to evaluate and estimate…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    West Virginia University Cancer Institute, Morgantown, West Virginia

    Run by

    West Virginia University

    See if you can join NCT06923488 on ClinicalTrials.gov

25. MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

    This is a Phase II study following subjects proceeding with Treosulfan (36g/m2) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion, with post-transplant cyclophosphamide (PTCy) at 40mg/kg, tacrolimus and MMF for GVHD prophylaxis.

    Stage

    Phase 2

    Ages

    2 to 75

    Site

    Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

    Run by

    Masonic Cancer Center, University of Minnesota

    See if you can join NCT07493538 on ClinicalTrials.gov